Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies

Li Qiao; Deliang Ma; Hui Lv; Ding Shi; Min Fei; Yu Chen; Fei Xie; Zhuoyan Wang; Ying Wang; Wanhua Liang; Peiying Hu

doi:10.1186/s13098-020-00598-0

Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies

Diabetol Metab Syndr. 2020 Oct 28:12:95. doi: 10.1186/s13098-020-00598-0. eCollection 2020.

Authors

Li Qiao¹, Deliang Ma¹, Hui Lv², Ding Shi³, Min Fei², Yu Chen², Fei Xie², Zhuoyan Wang², Ying Wang², Wanhua Liang¹, Peiying Hu²

Affiliations

¹ Department of Oncology, Linyi Central Hospital, 17 Jian Kang Road, Linyi, 276400 Shandong China.
² Health Promotion Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310006 Zhejiang China.
³ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, College of Medicine, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou, 310003 Zhejiang China.

Abstract

Background: Metabolic syndrome (MetS) has been related to the pathogenesis of variety categories of cancers. This meta-analysis aimed to determine the association between MetS and the incidence of lung cancer.

Methods: Relevant cohort studies were identified by search of PubMed, Embase, and Cochrane's Library databases. Cochrane's Q test and I² statistic were used to analyze the heterogeneity. Random-effect model which incorporates the potential heterogeneity was used for the meta-analysis.

Results: Five cohort studies with 188,970 participants were included. A total of 1,295 lung cancer cases occurred during follow-up. Meta-analyses showed that neither MetS defined by the revised NCEP-ATP III criteria (hazard ratio [HR]: 0.94, 95% confidence interval [CI]: 0.84 to 1.05, p = 0.25; I² = 0) nor the IDF criteria (HR: 0.82, 95% CI: 0.61 to 1.11, p = 0.20; I² = 0) was associated with an affected risk of lung cancer. Subgroup analyses showed consistent results in women and in men, in studies performed in Asian and non-Asian countries, and in prospective and retrospective cohorts (p all > 0.05). Meta-analysis limited to studies with the adjustment of smoking status also showed similar results (HR: 0.91, 95% CI: 0.80 to 1.05, p = 0.21; I² = 0). No publication bias was detected based on the Egger regression test (p = 0.32).

Conclusions: Current evidence from cohort studies does not support that MetS is an independent risk factor for the incidence of lung cancer.

Keywords: Cohort study; Lung cancer; Meta-analysis; Metabolic syndrome.